You are here

  • Home
  • Archive
  • Volume 92, Issue 5
  • N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study

Article Text

Article menu
Download PDFPDF
LETTERS
PostScript
N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study
  1. Afif F El-Khuffash1,
  2. Michele Amoruso2,
  3. Mary Culliton2,
  4. Eleanor J Molloy3
  1. 1Department of Neonatology, National Maternity Hospital
    Dublin, Republic of Ireland
  2. 2Department of Biochemistry, National Maternity Hospital
    Dublin, Republic of Ireland
  3. 3Department of Neonatology, National Maternity Hospital
    Dublin, Republic of Ireland
  1. Dr Afif Faisal El-Khuffash, Department of Neonatology, National Maternity Hospital, Holles Street, Dublin 2, Republic of Ireland; afif_faisal{at}hotmail.com

https://doi.org/10.1136/adc.2007.119701

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The diagnosis of a haemodynamically significant patent ductus arteriosus (sPDA) in preterm infants is often difficult, with echocardiography remaining the gold standard.1 However, availability and cost pose some difficulties. B-type natriuretic peptide (BNP) may assist diagnosis, but cut-off levels vary widely in the literature. No data exist on the applicability of the byproduct N-terminal pro-B-type natriuretic peptide (NTpBNP), which is more stable and has a longer half life.2 We hypothesised that NTpBNP may be useful in the management of preterm infants with sPDA and aimed to investigate its usefulness as a marker of sPDA and treatment success.

    Method

    The local ethics committee approved the study, and informed written parental consent was obtained from all parents prior …

    View Full Text

    Footnotes

    • This project was funded by the hospital's research fund which is accumulated from private donations from parents. Corporate donations are not used for research in this institution. We do not accept donations or sponsorships from drug companies.

    • Competing interests: None.